Safety and efficacy of a splenectomy during debulking surgery for Müllerian carcinoma

Purpose: This study was designed to assess the safety and efficacy of a splenectomy and to analyze the prognostic factors of Müllerian carcinoma with spleen metastasis. Methods: We reviewed the medical records of 11 patients with Müllerian carcinoma who underwent a splenectomy between 1997 and 2007. The treatment outcome of these patients was examined and the possible prognostic factors were investigated by univariate analysis. Results: Four and seven patients underwent a splenectomy for primary and recurrent disease, respectively. A complete resection was achieved in eight patients. A bloodtransfusion was not required and only two mild postoperative complications were observed. The median and five-year survivals of all patients following treatment were 39 months and 39%, respectively. Older patients ( 60 years old) and patients with a poor performance status (PS2) had a poorer prognosis by univariate analysis. Conclusions: A splenectomy can be performed safely and effectively during debulking surgery for appropriately selected patients with primary or recurrent Müllerian carcinoma.

Debulking surgery; Müllerian carcinoma; Prognosis; Spleen metastasis; Splenectomy

[1] Ozols R., Rubin S., Thomas G., Robboy S.: “Epithelial ovarian cancer”. In: Hoskins H., Perez C., Young R., Barakat R., Markman M., Randall M. (eds.). Principles and Practice of Gynecologic Oncology. 4th edition, Philadelphia: Lippincott Williams & Wilkins, 2005, 895.

[2] Panici P., De Vivo A., Bellati F., Manci N., Perniola G., Basile S. et al.: “Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer”. Ann. Surg. Oncol., 2007, 14, 1136.

[3] Nicklin J.L., Copeland L.J., O’Toole R.V., Lewandowski G.S., Vaccarello L., Havenar L.P.: “Splenectomy as part of cytoreductive surgery for ovarian carcinoma”. Gynecol. Oncol., 1995, 58, 244.

[4] Scarabelli C., Gallo A., Campagnutta E., Carbone A.: “Splenectomy during primary and secondary cytoreductive surgery for epithelial ovarian carcinoma”. Int. J. Gynecol. Cancer, 1998, 8, 215.

[5] Chen L.M., Leuchter R.S., Lagasse L.D., Karlan B.Y.: “Splenectomy and surgical cytoreduction for ovarian cancer”. Gynecol. Oncol., 2000, 77, 362.

[6] Ayhan A., Al R.A., Baykal C., Demirtas E., Ayhan A., Yuce K.: “The influence of splenic metastases on survival in FIGO Stage IIIC epithelial ovarian cancer”. Int. J. Gynecol. Cancer, 2004, 14, 51.

[7] Bilgin T., Ozerkan K., Ozan H.: “Splenectomy in cytoreductive surgery for advanced ovarian cancer”. Arch. Gynecol. Obstet.,2005, 271, 329.

[8] Eisenkop S.M., Spirtos N.M., Lin W.C.: “Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer”. Gynecol. Oncol., 2006, 100, 344.

[9] Magtibay P.M., Adams P.B., Silverman M.B., Cha S.S., Podratz

K. C.: “Splenectomy as part of cytoreductive surgery in ovarian cancer”. Gynecol. Oncol., 2006, 102, 369.

[10] Manci N., Bellati F., Muzii L., Calcagno M., Alon S.A., Pernice M. et al.: “Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data”. Ann. Surg. Oncol., 2006, 13, 1717.

[11] Deppe G., Zbella E.A., Skogerson K., Dumitru I.: “The rare indication for splenectomy as part of cytoreductive surgery in ovarian cancer”. Gynecol. Oncol., 1983, 16, 282.

[12] Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A. et al.: “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patientswith optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2003, 21, 3194.

[13] Eisenkop S.M., Friedman R.L., Spirtos N.M.: “The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma”. Cancer, 2000, 88, 144.

[14] Onda T., Yoshikawa H., Yasugi T., Yamada M., Matsumoto Taketani Y.: ‘Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection”. Br. J. Cancer, 2005, 92, 1026.